Celladon Corporation Reports Third Quarter 2014 Financial Results And Recent Highlights

Celladon Corporation , a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced financial results for the quarter ended September 30, 2014 and recent corporate highlights and updates. "Celladon had another productive quarter, in which we bolstered our balance sheet and observed progress across our product development portfolio.

http://ift.tt/1xt0cbf